Research Article Promising Health Benefits of Adjuvant Acmella and Zingiber Extracts Combined with Coenzyme Q10 Phytosomes, Supplementation in Chronic Pain Treated with Medical Cannabis: A Prospective and Open-Label Clinical Study Paolo Poli, 1 Simona Carnevale, 1 Antonella Scocca , 1 Pier Luigi Davolio, 2 Simona Busi, 2 Martino Meneghin, 3 Giovanna Petrangolini , 3 and Antonella Riva 3 1 Polipain Clinic, Pisa, Italy 2 Farmad Lab-R & D, Florence, Italy 3 Indena SpA, Research and Development Department, Milan, Italy Correspondence should be addressed to Antonella Riva; antonella.riva@indena.com Received 20 April 2022; Revised 11 May 2022; Accepted 26 May 2022; Published 13 June 2022 Academic Editor: Shuli Yang Copyright © 2022 Paolo Poli et al. is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background. Chronic pain is a condition where pain persists for months or even years. Nowadays, several drugs comprising of medical cannabis are utilized for chronic pain relief. Even if there are some associated side effects, the use of supplements can widen the reliable tools available for improving an individual’s quality of life. Objective. e aim of the present study was to evaluate the efficacy in terms of pain intensity, psychological well-being, and quality of life of a new dietary supplement in chronic pain subjects under current treatment with medical cannabis. Methods. In this pilot study, 48 medical cannabis-treated subjects were supplemented with a dietary supplement containing a combination of standardized Zingiber officinalis and Acmella oleracea extracts in phytosome (Mitidol), coenzyme Q10 phytosome (Ubiqsome), and group B vitamins (B1, B6, and B12), twice daily for 90 days. In order to explore the benefits of the product as an adjuvant supplementation for pain relief, the pain intensity, measured by the visual analogue scale (VAS), the pain type, and quality, evaluated by the Italian Pain Questionnaire (QUID) and the possible reduction of therapeutic and/or painkiller doses were recorded. Results. After 90 days, significant pain relief was detected in almost 70% of the subjects receiving the new dietary supplement, with sensory, emotional, and pain amelioration in one-third of them. A reduction in both tetrahydrocannabinol (THC) and cannabidiol (CBD) doses was also observed after 3 months of supple- mentation. ese findings demonstrate new perspectives for the use of an innovative dietary supplement that combines Acmella and Zingiber extracts, Coenzyme Q10, and group B vitamins resulting in a beneficial long-term adjuvant in cannabis-treated pain subjects. 1. Introduction Chronic pain is generally defined as pain refractory to standard treatment modalities. It is a stressing condition affecting 100 million people in Europe, impacting subjects’ quality of life. Different types of chronic pain exist, with the most represented being neuropathic pain, rheumatoid ar- thritis, headache, fibromyalgia, and central nervous sys- tem (CNS) disorders [1]. Cannabinoid prescriptions in Italy [2–5] are allowed for chronic pain and pain associated to multiple sclerosis, as well as other indications (i.e., HIV and cancer) [6–8]. However, therapy with medical cannabis would also be insufficient to control chronic pain or would cause collateral effects such as sleep problems, anxiety, or stress [9, 10]. Supplementation with natural products could help to reduce cannabis-related side effects or cannabis/painkiller use. erefore, the aim of the present investigation was to observe potential benefits of a long-term administration (90 Hindawi Evidence-Based Complementary and Alternative Medicine Volume 2022, Article ID 7099161, 6 pages https://doi.org/10.1155/2022/7099161